

GLOBAL TRENDS IN ANTIBIOTIC RESISTANCE AND AVAILABILITY – A REGULATOR’S PERSPECTIVE

Dr Joe Smith
Chief Executive Officer



Australian Pesticides and Veterinary Medicines Authority

1

OVERVIEW

- The issue
- Global perspectives
 - International forums
 - In-country developments
- Australia’s approach
- Dairy industry implications
- The future



2

ANTIBIOTIC RESISTANCE

- Human pathogen resistance
- Reasons
 - human use
 - animal use
- Today’s focus on animal use



VETERINARY USE OF ANTIBIOTICS

- Perceptions of control of use
- Antibiotic residues in meat, animal products
- Carriage of resistant bacteria
- Carriage of resistant genes



4

KEY IMPLICATIONS

- Availability of antibiotics
 - few new for human use
 - few new for animal use
 - existing products restricted/removed
- Trade



5

INTERNATIONAL FORUMS

- FAO/WHO/OIE Consultations – later speaker
- JECFA/Codex
 - Draft Code of Practice
 - MRLs for veterinary antibiotics
- VICH – data requirements
 - resistance development
 - microbiological ADIs
- APVMA actively engaged



JECFA/CODEX

- JECFA – expert committee
 - proposes MRLs
- CCRVDF
 - agrees MRLs
 - lengthy
- Recent AMR strategy

7

VICH

- Industry/regulatory authority
- International harmonised guidelines for veterinary medicine data requirements
 - Australia has adopted 29 (all)
- Working group for veterinary antibiotics
 - Potential for ABR
- At commencement – APVMA only authority with data requirement
 - Now being adopted in EU, US, Japan

8

IN-COUNTRY INITIATIVES

- UK, EU, USA, Canada, Australia, New Zealand
 - AMR strategies in place
- Animal and human aspects




COUNTRY STRATEGIES – SIX PILLARS

AMR STRATEGY




10

AUSTRALIA – PROACTIVE IN AMR



11

APVMA REGULATION



VETERINARY ANTIBIOTICS REGISTRATION

- Based on science, legislative criteria
- Expert advice on AMR
- Residues
 - potential dietary intake < ADI, ARfD



13

ISSUES FOR DAIRY INDUSTRY

- Restrictions on availability of antibiotics
 - prescription only
 - health and welfare of animals
- Little new AB development
- Alternatives to antibiotics
- Trade/market access implications



14

THE FUTURE

- Continued concerns
 - medical community
 - public
- Improved communications
- Diminishing new products
 - preserve existing



THE FUTURE (cont.)

- Further access/use restrictions
 - human, animal
- Increased focus on AMR in registration
 - microbiological end-points
- Trade challenges
- Cooperative, science-based solutions



16